Table 5.

Alzheimer’s disease drug consumption reimbursed by NHS (territorial and public pharmacies) and percentage of private purchase in the general population (2019)

ADDs	Reimbursed by NHS	Private purchase	Percentage of private purchase**
	DDD/1000 inhab per day	DDD/1000 inhab per day
AChEIs	0.40	0.24	37.5
Rivastigmine	0.11	0.04	27.9
Galantamine	0.01	< 0.005	25.0
Donepezil	0.28	0.19	40.9
Other ADDs
Memantine	0.28	0.17	13.1
Total ADDs	0.68	0.41	37.9

^**Private purchase is obtained as a difference between what is purchased from pharmacies (sell-in, pharmaceutical companies feed this database), compared to what is paid by the NHS (sell-out, i.e. the Osmed flow), considering citizens as a recipient. It should be noted that when analysing the consumption related to a wide time span, any misalignment between sell-in and sell-out is minimized, consequent to the re-composition of the warehouse stocks of the pharmacy, which on the contrary could affect significantly on the single month

Bold indicates the overall data for ADDs